Meta-analysis · people
Teriparatide cut fracture risk vs bisphosphonates (RR 0.61)
Checked against the paper Meta-analysisPublished by PepVault
The takeaway
Across 23 head-to-head trials, teriparatide beat bisphosphonates on fracture risk and bone density in people not previously on a bisphosphonate, without more adverse events.
- Kind
- Meta-analysis
- Studied in
- People
- Number studied
- 6680
- Published
- 2024
- Journal
- Arch Osteoporos
What they tested
The team set out to compare how well and how safely teriparatide and denosumab work against bisphosphonates in people with osteoporosis who had never taken a bisphosphonate.
How the study was done
A systematic review and meta-analysis, which pools results from many studies, of 23 head-to-head randomized controlled trials with 6680 patients in total. Each trial compared teriparatide or denosumab directly with a bisphosphonate.

What they found
Teriparatide lowered the risk of fracture compared with bisphosphonates, with a risk ratio (RR, how the risk in one group compares with the other) of 0.61 (95% CI 0.51 to 0.74, P < 0.001). Denosumab did not lower fracture risk compared with bisphosphonates (RR 0.99, 95% CI 0.62 to 1.57, P = 0.96). Both teriparatide and denosumab raised bone mineral density, a measure of how dense the bone is, at the femoral neck, total hip and lumbar spine more than bisphosphonates did (P < 0.05). Neither raised the rate of adverse events: teriparatide RR 0.92 (P = 0.32) and denosumab RR 0.98 (P = 0.37).
What it doesn’t show
The pooled trials differed from each other clinically, so the team used both fixed-effect and random-effect models. It covers only people who had not had a bisphosphonate before, so it doesn't speak to people switching from one.
The paper
Li et al. Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials. Arch Osteoporos. 2024.
The compound
More studies on Teriparatide
- Abaloparatide, teriparatide beat other drugs on spine BMD in menMeta-analysis · people · 2025
- Abaloparatide: larger hip BMD gains than teriparatide at 24 weeksMeta-analysis · people · 2023
- Teriparatide: more bony union at 6 months than zoledronate after PLIFRandomized trial · people · 2022
- Teriparatide: 45.4% of jaw osteonecrosis lesions resolved by 52 weeksRandomized trial · people · 2020
- Teriparatide: fewer new vertebral fractures than risedronate in VERORandomized trial · people · 2018
- Teriparatide then denosumab: spine density up 18.3% over 4 yearsRandomized trial · people · 2015
- Every study on Teriparatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.